KBKalpana Babu

Kalpana Babu

*This is an algorithmically generated author record based on publicly available information.

Kalpana Babu has a total of 55 co-authors. Here are the top co-authors by number of shared publications:

  • Krishna R Murthy

    Department of Vitreoretina, Prabha Eye Clinic and Vittala International Institute of Ophthalmology, Bengaluru, Karnataka, India

    7 shared publications
  • Vinaya Kumar Konana

    Department of Vitreoretinal Services, Vittala International Institute of Ophthalmology, Bengaluru, Karnataka, India

    6 shared publications
  • Bhagya Sudheer

    Department of Uveitis and Ocular Inflammation, Vittala International Institute of Ophthalmology and Prabha Eye Clinic and Research Centre, Bengaluru, Karnataka, India

    5 shared publications
  • Ramesh Jois

    Department of Rheumatology, Rheumacare, Bengaluru, Karnataka, India

    4 shared publications
  • Vidya Mooss

    Department of Uvea and Ocular Inflammation, Prabha Eye Clinic and Research Centre and Vittala International Institute of Ophthalmology, Bengaluru, Karnataka, India

    4 shared publications
  • Anand P Rao

    Department of Pediatric Rheumatology, Manipal Hospitals, Old Airport Road and Indira Gandhi Institute of Child Health, Bengaluru, Karnataka, India

    3 shared publications

Latest Publications

  • Open Access

    Ocular involvement in Takayasu arteritis – A case series from a tertiary eye center in South India

    by Kalpana Babu, Vidya Mooss, Ramesh Jois

    Purpose: To analyze the clinical profile of patients with Takayasu arteritis (TAK) from a South Indian patient population who presented to a tertiary referral eye center. Methods: Retrospective case series between 2016 and 2025. Results: Of the 13 cases of TAK, 11 were females and 2 were males (female: male = 11:2). The mean age was 31.92 ± 7.04 years. Nine cases initially presented to an ophthalmologist. The most common presenting symptoms were eye pain (eight cases) and diminution of vision (seven cases), of whom two had sudden vision loss. Ocular involvement included ocular ischemia with retinal vessel spasm and constriction (three cases), Takayasu retinopathy (three cases), and central retinal artery occlusion (one case). Optic disc pallor, dilated conjunctival and episcleral vessels, scleritis, hypertensive retinopathy, and atypical Tolosa Hunt syndrome were other presentations. Presumed ocular tuberculosis in two cases led to an incidental diagnosis of TAK. Based on the imaging findings, six cases had type I TAK, five cases had type V TAK, and one case each had type IV and type IIa TAK. Treatment included systemic corticosteroids and conventional disease-modifying antirheumatic drugs (methotrexate and mycophenolate mofetil) and tocilizumab. Good visual outcome on early treatment was seen in our series. Conclusion: TAK is an important and underrecognized cause of ocular inflammation and ischemia in young patients. Our series highlights that ocular involvement can precede systemic diagnosis. Early diagnosis and treatment results in a good visual outcome.

  • Tofacitinib for Refractory Non-Infectious Ocular Inflammation: A Retrospective Observational Study

    by Vidya S. Mooss, Kalpana Babu, Haridas Mundot Puliappadamb

    Non-infectious ocular inflammatory diseases often require long-term immunomodulatory therapy (IMT) to prevent relapses and vision-threatening complications. Although conventional and biologic immun...

  • Open Access

    Tofacitinib: New drug in the therapeutic armamentarium in ocular inflammation

    by Kalpana Babu, Vidya Mooss

    Tofacitinib, an oral Janus kinase (JAK) inhibitor, has established efficacy in the management of several autoimmune and inflammatory disorders, including rheumatoid arthritis, psoriatic arthritis, dermatitis, and ulcerative colitis. By inhibiting JAK phosphorylation, tofacitinib modulates cytokine-mediated inflammatory responses through interference with the JAK-STAT signaling pathway. In recent years, accumulating real-world evidence from India has suggested a beneficial role for tofacitinib in the management of ocular inflammatory diseases, particularly in patients with refractory disease who have failed conventional disease-modifying antirheumatic drugs and biologic therapies. Factors such as oral administration, rapid clinical response, ease of monitoring, and relative affordability compared with biologics have facilitated its wider adoption in routine clinical practice in the Indian setting. This review discusses the drug tofacitinib, mode of action, safety profile, its utility in non-infectious uveitis and with a particular emphasis on real-world data and socioeconomic considerations relevant to resource-limited settings.

  • Open Access

    Clinical profile and treatment outcomes in acute retinal necrosis in a South Indian patient population

    by Vidya S Mooss, Krishna R Murthy, Kalpana Babu, Aniruddha A Tirumalai

    Purpose: To look at the clinical profile, treatment methods, and outcomes in cases of acute retinal necrosis (ARN) from a tertiary eye care center. Methods: Hospital-based retrospective observational study wherein cases of ARN presented between January 2016 and December 2023 were reviewed. Demographic details, clinical presentation, complications, management, and visual outcome were evaluated. Results: Twenty eyes of 18 cases were included in the study. Mean age was 40.77 ± 16.38 years, male to female ratio was 2:1, and 11.11% had bilaterality at presentation. Mean duration of uveitis was 3.312 ± 0.95 months. The most commonly found organism was VZV (50%), followed by HSV (45%). All cases were given intravitreal ganciclovir in addition to systemic antivirals and oral steroids. The mean number of intravitreal injections was 5.53 ± 3.87. Maintenance dose of oral valacyclovir (500 mg twice daily) was continued in all cases for an average duration of 5.61 ± 3.79 months. The most common complications noted were retinal detachment (50%) followed by optic atrophy (44.44%). No significant association was noted between the extent of retinitis and the development of complications ( P = 0.215). However, there was a significant difference seen in the rate of complications between the HSV and VZV groups, with more complication rates seen with the VZV group ( P = 0.04). The mean visual acuity was 0.87 ± 0.85 logMAR at presentation and 0.65 ± 0.67 logMAR at the end of the study. Conclusion: Timely diagnosis, aggressive initial treatment with intravitreal ganciclovir along with systemic antivirals and long-term maintenance therapy with systemic antivirals are crucial in ARN to obtain the best visual prognosis achievable and prevent lifelong disabilities.


  • Open Access

    Current concepts in the diagnosis of ocular tuberculosis: A narrative review

    by Vinaya Kumar Konana, Kalpana Babu

    Ocular tuberculosis (OTB) is one of the extrapulmonary manifestations caused by Mycobacterium tuberculosis (Mtb). If untreated, it can result in poor visual prognosis. Prompt diagnosis of OTB is met with challenges. The gold standard for the diagnosis of OTB is the direct demonstration of the Mtb in ocular tissues or ocular fluids either by Ziehl–Neelsen Stain, culture or molecular diagnostic techniques such as polymerase chain reaction. This is onerous owing to the paucibacillary nature of the disease, small quantity of samples, and low sensitivity and specificity of molecular diagnostic tests. Thus, one needs to rely on indirect evidences to make a diagnosis. Hence, most often, the diagnosis of OTB is presumed based on the geography the patient hails from and indirect laboratory evidences suggestive of TB. In this narrative review, we review clinical, laboratory, and radiology markers which aid in the diagnosis of OTB and outline the current concepts in the diagnosis of OTB.


  • Open Access

    Rosai–Dorfman disease presenting as a scleral nodule in a female with multisystem inflammatory syndrome post-COVID-19 infection

    by Nashra Alma, Smitha Kuthyar Shambu, Kalpana Babu

    We report a rare presentation of Rosai–Dorfman disease (RDD) as scleritis transforming to a nodule in a female with multisystem inflammatory syndrome following COVID-19 infection. A 54-year-old female presented to us first in August 2022 with redness and slight discomfort in both eyes of 2 weeks’ duration. She had a history of multisystem inflammatory syndrome post-COVID-19 infection. Although she presented with scleritis (oculus uterque), it continued to persist with a course of oral and topical steroids. Laboratory investigations including autoimmune profile were negative. Only QuantiFERON-TB Gold test was positive. High-resolution computed tomography showed a few subcentimeter enlarged mediastinal lymph nodes and a cluster of enlarged cervical lymph nodes. Biopsy showed chronic granulomatous inflammation with no caseation, negative for Mycobacterium tuberculosis. Over a year, this transformed to a scleral nodule. Excision biopsy confirmed RDD disease. Whole body positron emission tomography-computerized tomography confirmed no active lesions elsewhere. She was started on methotrexate. At 1-year follow-up, there was no recurrence.


  • Acinetobacter baumannii Endogenous Endophthalmitis Presenting with Iris Nodules

    by Kalpana Babu, S. Chandana, Aniruddha Tirumalai, Krishna R. Murthy

    Aim: We report a unique finding of iris nodules in a woman with endogenous endophthalmitis due to Acinetobacter baumannii with no history of ocular surgery or trauma and good visual outcome. Materials & Methods: Retrospective case report. Results: A 39-year-old woman with a history of type 2 diabetes mellitus presented with a decrease in vision in the right eye of 1-month duration. On examination, her BCVA was CF2m (OD) and 6/6 (OS). Right eye examination showed medium-to-large-sized keratic precipitates, iris nodules, and vitritis. PCR on the aqueous showed faint positivity for Propionibacterium acne and was negative to panfungal genome. Despite two intravitreal injections of vancomycin (1 mg/0.1 ml) and intravenous cefazolin 1 g bd for 5 days, there was progression to hypopyon. Vitrectomy with lensectomy was done. The vitreous culture grew Acinetobacter baumannii. She was given multiple intravitreal ceftazidime (2.25 mg/0.1 ml) with dexamethasone (0.4 mg/0.1 ml) injections. She was also put on tab bactrim DS twice a day for 3 months along with tab doxycycline 100 mg twice a day for 3 months by the infectious disease specialist. As the inflammation improved, the iris nodules were the last to resolve completely in 6 weeks. At 15-month follow-up, her eye was quiet, and vision was 6/9 (OD) with aphakic correction. Conclusion: We report a rare finding of iris nodules in a patient with culture proven Acinetobacter baumannii endogenous endophthalmitis.


  • Open Access

    Biologics in ocular inflammatory diseases – Experience from a tertiary referral eye care center in South India

    by Kalpana Babu, Pg Padmapriya, Anand P Rao, Ramesh Jois

    Purpose: To analyze the utility of biologics in noninfectious uveitis and other ocular inflammatory diseases in a South Indian patient population. Methods: This was a retrospective observational study conducted at the uveitis and ocular inflammatory diseases clinic of a tertiary eye care hospital in South India between 2016 and 2023. Results: Records of 76 patients on biologics were retrieved from our databases. The mean age was 34.84 ± 17.383 years. In 75% of patients, the duration of follow-up was 52.75 months. Overall, anterior nongranulomatous uveitis was the most common anatomic type of uveitis (34.21%). HLA B27-associated uveitis was the most common etiology (34.21%) in whom biologics were used. Patients P = 0.001). Adverse effects were seen in 14 patients (18.42%). The success rate of biologics was low in the parsplanitis group <18 years (33.3%), Blau-associated uveitis (50%), and idiopathic uveitis (30%). Conclusion: In this study, we have analyzed the results of biologics in different anatomic types of ocular inflammation and etiologies. The success rate of biologics was low in parsplanitis, idiopathic uveitis, and Blau-associated uveitis and higher in other etiologies.


  • Open Access

    Cone dysfunction in patients with ethambutol toxicity

    by Vinaya K Konana, Vidya Mooss, Kalpana Babu


  • Open Access

    Hemophilus influenzae-associated scleritis – A case report with a review of the literature

    by Kalpana Babu, V Raksha, Krishna R Murthy

    We report a challenging clinical course of Hemophilus influenzae ( H. influenzae ) scleritis with a review of the literature. A 62‐year‐old lady with a history of progressing necrotizing scleritis over 7 months, negative for infection on scleral explorations, was given pulse doses of intravenous cyclophosphamide after she failed conventional immunomodulation. After two doses, she developed a tiny area of pus pointing, which was explored and subjected to microbiology. Though cultures were negative, PCR showed H. influenzae . She received intravenous ceftriaxone [2 g/day for 5 days], oral clarithromycin [500 mg twice daily for 14 days] and hourly fortified piperacillin, tazobactam and ceftazidime eyedrops. In addition, she received subconjunctival injections of ceftazidime. At 4 months follow‐up, the scleritis had resolved completely. At 1 year follow‐up, there was no recurrence of scleritis. H. influenzae is a rare cause of infectious scleritis. This case highlights the diagnostic challenge and the clinical course in such a case.